• About
  • Services
  • Profiles
  • News
  • Contact

RMMS Shortlisted for the “Firm of the Year - Life Sciences IP Litigation” by Managing Intellectual Property

03/08/2023

RMMS Obtains IPR Victory Related To Aflibercept

11/10/2022

RMMS Receives Continued Recognition in IAM Patent 1000 – Two Firm Partners Individually Ranked

07/06/2022

RMMS Ranked Nationally for Life Sciences IP – William Rakoczy Again Recognized as IP Star

06/15/2022

RMMS Recognized as a “Firm to Watch” by The Legal 500

06/08/2022

RMMS Again Recognized by Chambers & Partners – RMMS, William Rakoczy Ranked Nationally for Life Sciences

06/03/2022

Federal Circuit Affirms Judgment Involving DUEXIS® Tablets (800 mg ibuprofen and 26.6 mg famotidine

11/16/2021

RMMS Secures Non-Infringement and Invalidity Win on BROMSITE® (bromfenac ophthalmic solution) 0.075%

10/01/2021

RMMS Expands Life Science Team with Addition of Kevin Warner

09/09/2021

RMMS Partner Tara M. Raghavan Installed as President-Elect of the South Asian Bar Association of North America

07/21/2021

RMMS Receives Continued Recognition in IAM Patent 1000 – Five Firm Partners Individually Ranked

07/02/2021

RMMS Ranked Nationally for Life Sciences IP - Paul Molino & William Rakoczy Again Recognized as IP Stars

06/18/2021

RMMS Again Recognized by Chambers & Partners - William Rakoczy Ranked Nationally for Life Sciences

05/24/2021

RMMS Scores Win in Case Involving DUEXIS® tablets (800 mg ibuprofen and 26.6 mg famotidine)

11/30/2020

LMG Life Sciences Hall of Fame Welcomes RMMS Founding Partner William Rakoczy

09/28/2020

RMMS Nominated For 2020 LMG Life Sciences Awards

08/03/2020

RMMS Scores Win in Case Involving CLENPIQ®

06/23/2020

RMMS Again Recognized as Litigation Leader in IAM Patent 1000 – Firm Partners Receive Individual Recognition

06/11/2020

RMMS Partners Paul Molino & William Rakoczy Recognized as IP Stars

05/07/2020

RMMS Recognized as Leading Lawyers by Chambers USA

04/23/2020

RMMS Secures Favorable Resolution in BPCIA Litigation Involving FULPHILA® (pegfilgrastim-jmdb)

11/01/2019

RMMS Awarded Impact Case of the Year by LMG Life Sciences

09/18/2019

RMMS Nominated For LMG Life Sciences Awards

07/22/2019

RMMS Recognized as Litigation Leader in IAM Patent 1000 - William Rakoczy and Deanne Mazzochi Receive Individual Recognition

06/10/2019

RMMS Recognized Nationally and Regionally for Life Sciences Litigation - William Rakoczy and Paul Molino Selected as IP Stars

04/02/2019

RMMS Files Supreme Court Amicus Brief on Behalf of AAM Challenging The Federal Circuit’s Reading Of The IPR Time Bar Under Section 315(b)

02/13/2019

RMMS Secures Favorable Claim Construction Ruling in NEULASTA® (pegfilgrastim) BPCIA Litigation

11/20/2018

Federal Circuit Affirms Invalidity Judgment Concerning COPAXONE® (Glatiramer Acetate)

10/12/2018

RMMS Recognized as Industry Leaders by LMG Life Sciences for Seventh Consecutive Year

09/27/2018

RMMS Listed as Highly Recommended Patent Firm by Managing IP; William A. Rakoczy and Paul J. Molino Recognized as IP Stars

06/22/2018

RMMS Partner Deanne M. Mazzochi Recognized as a Top Lawyer among Leading Women Lawyers in Illinois by Leading Lawyers

06/22/2018

RMMS Recognized as a Leading Patent Firm in Litigation by IAM Patent 1000; William A. Rakoczy Individually Ranked “Gold” in Litigation by IAM Patent 1000

06/22/2018

Federal Circuit Affirms Invalidity Judgment Concerning AXIRON® (Testosterone) Transdermal Solution

11/22/2017

RMMS Partner William Rakoczy Recognized by Chambers & Partners

07/28/2017

RMMS Scores Win in Europe Relating to Shire’s Factor VIII ADVATE Franchise

05/16/2017

RMMS Named “U.S. Firm to Watch” by Managing Intellectual Property Magazine

03/23/2017

Federal Circuit Affirms Collateral Estoppel Decision Concerning Latisse® (bimatoprost topical solution)

03/17/2017

RMMS Secures Invalidity Win on Copaxone® 40 (glatiramer acetate 40 mg/mL)

01/30/2017

RMMS Secures Invalidity And Non-Infringement Victories on Patents Related To Axiron® (Testosterone) Transdermal Solution

08/22/2016

RMMS Recognized As Second Most Active Firm Representing Defendants in Hatch-Waxman Cases

04/27/2016

Federal Circuit Affirms Judgment of Invalidity Concerning OxyContin® (oxycodone extended-release tablets)

02/01/2016

RMMS Secures Favorable Claim Construction Ruling In Suit Involving Generic Aripiprazole (Abilify®)

11/16/2015

RMMS Recognized as Industry Leaders by LMG Life Sciences for Fourth Consecutive Year

10/20/2015

RMMS Secures Summary Judgment Against Otsuka Related To Generic Aripiprazole (Abilify®)

05/27/2015

Federal Circuit Affirms Judgment of Invalidity Concerning Pulmicort Respules® (budesonide inhalation suspension)

05/07/2015

RMMS Secures Second Victory Against Otsuka Related To Generic Aripiprazole (Abilify®)

04/30/2015

Chief Judge Simandle Allows Launch of Generic Aripiprazole (Abilify®)

04/16/2015

Federal Circuit Affirms Invalidity Judgment Concerning Zymaxid®/Zymar® (Gatifloxacin) Ophthalmic Solutions

03/20/2015

RMMS Files Supreme Court Amicus Brief on Behalf of GPhA Supporting Specific-Intent-to-Infringe Requirement for Induced Infringement

02/26/2015

RMMS Secures Judgment of Patent Invalidity Following Remand Trial Involving Generic Pulmicort Respules® (Budesonide Inhalation Suspension)

02/13/2015

Federal Circuit Affirms Judgment Of Non-Infringement Involving Generic Trizivir® (Abacavir Sulfate, Lamivudine, and Zidovudine) Tablets

02/12/2015

RMMS Recognized as Industry Leaders by LMG Life Sciences

11/07/2014

RMMS Secures Reversal Before Federal Circuit, Invalidating Asserted Patents Concerning Latisse® (bimatoprost) Ophthalmic Solution

07/10/2014

U.S. Court Of Appeals For The Federal Circuit Affirms RMMS's Victory Involving Generic Ibandronate Products

04/11/2014

RMMS Secures Judgment Of Non-Infringement After A Trial Involving Generic Trizivir® (Abacavir Sulfate; Lamivudine; Zidovudine) Tablets

12/17/2013

rmms-secures-judgment-of-patent-invalidity-after-a-trial-involving-gatifloxacin-ocular-formulation-and-method

08/09/2013

Federal Circuit Affirms Judgment Of Non-Infringement Involving Generic Mometasone Furoate Nasal Spray

06/10/2013

RMMS Secures Judgment Of Patent Invalidity And Non-Infringement After A Trial Involving Budesonide Inhalation Suspension

04/01/2013

RMMS Defeats Motion for Preliminary Injunction Involving Generic Tiagabine Hydrochloride Products

12/20/2012

RMMS LLP recognized as one of the top Hatch-Waxman litigation firms in the country by LMG Life Sciences

06/16/2012

RMMS Secures Judgment Of Non-Infringement After A Trial Involving Generic Mometasone Furoate Nasal Spray

06/15/2012

RMMS Defeats Motion for Preliminary Injunction Involving Generic Ibandronate Products

03/14/2012

RMMS Secures Summary Judgment of Non-Infringement Involving Generic Guaifenesin Extended-Release Tablets, 600 mg

01/11/2012

RMMS Defeats Motion for Preliminary Injunction Involving Generic Carbamazepine Extended-Release Capsules

07/06/2011

RMMS Secures Federal Circuit Ruling Affirming Trial Decision of Patent Invalidity Involving Generic Galantamine

09/25/2009

RMMS Defeats Motion for Temporary Restraining Order Involving Generic Piperacillin/Tazobactam Injections

09/24/2009

RMMS Secures Federal Circuit En Banc Ruling Affirming Summary Judgment Of Noninfringement Involving Generic Cefdinir

05/19/2009

RMMS Defeats Motion for Temporary Restraining Order and Preliminary Injunction Involving Generic Ramipril Capsules

06/10/2008

RMMS Defeats Motion for Preliminary Injunction Involving Generic Clobetasol Propionate Foam Products

03/19/2008

RMMS Defeats Motion for Preliminary Injunction for Generic Client in Patent Dispute

04/26/2006

RMMS Wins Summary Judgment of Non-Infringement for Generic Client in Patent Dispute Involving Pfizer's Blockbuster Prescription Drug Neurontin®

08/22/2005

RMMS Wins Summary Judgment of Non-Infringement for Generic Client in Patent Dispute Involving Pfizer's Blockbuster Prescription Drug Neurontin®

08/22/2005

RMMS Attorney Testifies Before Congress On Important Patent Reform Issues

07/15/2005

Services

  • Litigation
    • Small Molecules and Biologics
    • Regulatory Litigation
    • Representative Matters
    • Litigation Highlights
  • Patent Counseling
  • Regulatory Counseling
    • About
    • Services
    • Profiles
    • News
    • Contact
    • Disclaimers
    • Copyright © 2022 Rakoczy Molino Mazzochi Siwik LLP